Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.

(2021) Scott Randall Plotkin et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)

(2021) Matthias Preusser et al.   NEURO-ONCOLOGY

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

(2020) Thomas Graillon et al.   CLINICAL CANCER RESEARCH

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis

(2020) Christian Mirian et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas

(2020) Philipp Sievers et al.   ACTA NEUROPATHOLOGICA

Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic

(2020) Erik A. Williams et al.   Acta Neuropathologica Communications

Analysis of Prognostic Factors of World Health Organization Grade Ⅲ Meningiomas

(2020) Weidong Tian et al.   Frontiers in Oncology

Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management

(2020) Taylor Anne Wilson et al.   Frontiers in Oncology

Clinical Validation of a Cell-Free DNA Gene Panel

(2019) Ju Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome

(2018) Tareq A. Juratli et al.   ACTA NEUROPATHOLOGICA

Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p

(2018) Philipp Sievers et al.   ACTA NEUROPATHOLOGICA

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

(2017) Felix Sahm et al.   LANCET ONCOLOGY

BAP1 mutations in high-grade meningioma: implications for patient care

(2017) Ganesh M Shankar et al.   NEURO-ONCOLOGY

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas

(2017) Tareq A. Juratli et al.   Oncotarget

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2016) J. C. Soria et al.   ANNALS OF ONCOLOGY

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas

(2016) Victoria E Clark et al.   NATURE GENETICS

Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma

(2016) Malak Abedalthagafi et al.   NEURO-ONCOLOGY

TERT Promoter Mutations and Risk of Recurrence in Meningioma

(2015) Felix Sahm et al.   JNCI-Journal of the National Cancer Institute

NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI)

(2015) Benjamin Ellingson et al.   NEURO-ONCOLOGY

TERT Promoter Mutations and Risk of Recurrence in Meningioma

(2015) Felix Sahm et al.   JNCI-Journal of the National Cancer Institute

Anchored multiplex PCR for targeted next-generation sequencing

(2014) Zongli Zheng et al.   NATURE MEDICINE

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

(2014) T. Kaley et al.   NEURO-ONCOLOGY

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

(2014) I. M. Shapiro et al.   Science Translational Medicine

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

(2013) Y. Yan et al.   CLINICAL CANCER RESEARCH

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

(2013) Priscilla K Brastianos et al.   NATURE GENETICS

Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO

(2013) V. E. Clark et al.   SCIENCE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation

(2012) M Peyre et al.   ONCOGENE

A framework for variation discovery and genotyping using next-generation DNA sequencing data

(2011) Mark A DePristo et al.   NATURE GENETICS

Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status

(2010) S. Goutagny et al.   CLINICAL CANCER RESEARCH

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Synthetic Lethality — A New Direction in Cancer-Drug Development

(2009) J. Dirk Iglehart et al.   NEW ENGLAND JOURNAL OF MEDICINE